The single solution
On a crisp sunny day in late March, fee earners from 39 law firms gathered at the corporate headquarters of pharmaceuticals giant Pfizer, a nondescript office building a couple of blocks east of Grand Central Station in New York. The collective mood was cheerful. After all, each of the firms still had a piece of Pfizer's US litigation work. Two years earlier, the company had dumped 80% of its hundreds of outside counsel in a convergence project called P3 - the Pfizer Partnering Programme. Now, representatives from the survivors had been convened to receive an update.There was nothing surprising in what the first speaker, Sandra Phillips, head of the company's product litigation group, had to say. But the second speaker had some unexpected news to deliver. Margaret Madden (pictured right), head of Pfizer's employment law group, explained how her staff had slashed its roster of 50 outside law firms in the first phase of P3 to 10. A quick look around the room, however, revealed that just one of those employment firms was present. What happened to the other nine?
This premium content is reserved for
Legal Week Subscribers.
A PREMIUM SUBSCRIPTION PROVIDES:
- Trusted insight, news and analysis from the UK and across the globe
- Connections to senior business lawyers within the leading law firms and legal departments
- Unique access to ALM's unrivalled, market-leading reporting in the US and Asia and cutting-edge research, including Legal Week's UK Top 50 and Global 100 rankings
- The Legal Week Daily News Alert, Editor's Highlights, and Breaking News digital newsletters and more, plus a choice of over 70 ALM newsletters
- Optimized access on all of your devices: desktop, tablet and mobile
- Complete access to the site's full archive of more than 56,000 articles
Already have an account? Sign In Now
For enterprise-wide or corporate enquiries, please contact Paul Reeves on Preeves@alm.com or call on +44 (0) 203 875 0651